

10/009809 ~~75~~

26 APR 2002

SEQUENCE LISTING

<110> Eisenberg, Ronit  
Raz, Tamar

<120> Novel Anti-Allergic Agents

<130> 24025-501 NATL

A 1  
<140> 10/009,809  
<141> 2000-06-14

<150> PCT/IL00/00346  
<151> 2000-06-14

<150> IL 130526  
<151> 1999-06-17

<160> 21

<170> PatentIn Ver. 2.1

<210> 1  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 1  
Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr  
1 5 10

<210> 2  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 2  
Lys Asn Asn Leu Lys Asp Cys Gly Leu Phe  
1 5 10

<210> 3  
<211> 16  
<212> PRT  
<213> Homo sapiens

<400> 3  
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro  
1 5 10 15

<210> 4  
<211> 15  
<212> PRT  
<213> Homo sapiens

<400> 4

Val Thr Val Leu Ala Leu Gly Ala Leu Ala Gly Val Gly Val Gly  
1 5 10 15

<210> 5

<211> 16

<212> PRT

<213> Drosophila acanthoptera

A ( <400> 5

Arg Gln Pro Lys Ile Trp Phe Pro Asn Arg Arg Lys Pro Trp Lys Lys  
1 5 10 15

<210> 6

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 6

Val Thr Val Leu Ala Leu Gly Ala Leu Ala Gly Val Gly Val Gly Lys  
1 5 10 15

Asn Asn Leu Lys Glu Cys Gly Leu Tyr  
20 25

<210> 7

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 7

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro  
1 5 10 15

Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr  
20 25

<210> 8

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<220>  
<221> VARIANT  
<222> (1)..(26)  
<223> N-terminal amino acid is succinylated

<400> 8  
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro  
1 5 10 15  
  
Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr  
20 25

A |  
<210> 9  
<211> 26  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<220>  
<221> VARIANT  
<222> (7)  
<223> A bond exists between the side chain of Lys and  
the C-terminus of the peptide.

<400> 9  
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro  
1 5 10 15  
  
Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr  
20 25

<210> 10  
<211> 26  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 10  
Arg Gln Pro Lys Ile Trp Phe Pro Asn Arg Arg Lys Pro Trp Lys Lys  
1 5 10 15  
  
Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr  
20 25

<210> 11  
<211> 25  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 11

Val Thr Val Leu Ala Leu Gly Ala Leu Ala Gly Val Gly Val Gly Lys  
1 5 10 15

Glu Asn Leu Lys Asp Cys Gly Leu Phe  
20 25

A 1

<210> 12

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 12

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro  
1 5 10 15

Lys Glu Asn Leu Lys Asp Cys Gly Leu Phe  
20 25

<210> 13

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 13

Arg Gln Pro Lys Ile Trp Phe Pro Asn Arg Arg Lys Pro Trp Lys Lys  
1 5 10 15

Lys Glu Asn Leu Lys Asp Cys Gly Leu Phe  
20 25

<210> 14

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 14  
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro  
1 5 10 15

Lys Asn Asn Leu Lys Asp Cys Gly Leu Phe  
20 25

<210> 15  
<211> 26  
<212> PRT  
<213> Artificial Sequence

*A* |  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<220>  
<221> VARIANT  
<222> (1)..(26)  
<223> N-terminal amino acid is succinylated

<400> 15  
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro  
1 5 10 15

Lys Glu Asn Leu Lys Asp Cys Gly Leu Phe  
20 25

<210> 16  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 16  
Lys Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala  
1 5 10 15

Pro Lys Asn Asn Leu Lys Asp Cys Gly Leu Phe  
20 25

<210> 17  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 17

Lys Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala  
1 5 10 15

Pro Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr  
20 25

<210> 18  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

A) <400> 18  
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro  
1 5 10 15

Leu Lys Glu Cys Gly Leu Tyr  
20

<210> 19  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 19  
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro  
1 5 10 15

Leu Lys Asp Cys Gly Leu Phe  
20

<210> 20  
<211> 26  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 20  
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro  
1 5 10 15

Lys Asn Asn Leu Lys Glu Ser Gly Leu Tyr  
20 25

<210> 21  
<211> 26  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<220>  
<221> VARIANT  
<222> (1)..(2)  
<223> Ala in D/L configuration

<400> 21  
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro  
1 5 10 15

Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr  
20 25

1000 900 800 700 600 500 400 300 200 100 0

A  
Core